Microviable Therapeutics Announces 1.5 Million Euros Investment to Advance the Company´s Microbiota-Derived Biotherapeutic Products
19.4.2022 12:00:00 EEST | Business Wire | Press release
Microviable Therapeutics SL, a preclinical stage biotechnology company developing orally administered biological drugs based on microbiota-derived products, announced 1.5 million euros seed funding from the private medical group Inmunomet Intolerancia y Disbiosis SL.
Microviable will use the seed funding to enhance their therapeutic development platform and advance their pipeline to the clinical stage. The lead product, MVT-201, is under evaluation at pre-clinical stage with positive results, and it is an unique in its kind biological drug based on complete microbiota (HiPMTM) for undisclosed targets. The microbiota-derived product development platform also includes rationally design and defined bacterial consortia that will be advanced with this funding.
This investment will enable to consolidate Microviable’s growth and focus towards the therapeutics, while increasing their facilities and headcount.
“We are really excited for Microviable´s future and grateful for this opportunity to bring novel solutions to healthcare with the ultimate goal of improving the patients’ quality of life”, said Claudio Hidalgo Cantabrana, PhD, co-founder and CEO at Microviable. “We wanted a strategic partner that shares our vision of using microbiota-derived biological drugs to treat patients while providing smart capital, and Inmunomet fulfills all of our expectations”.
Inmunomet is a private medical group specialized in intolerances and gut dysbiosis related disorders with strong experience on the clinic. With this investment, Inmunomet is seeking to be part of Microviable´s growth being ahead on the development of novel solutions based on microbiota-derived biotherapeutic products. Inmunomet provides not only the funding but smart capital and synergies on the clinic, very well aligned with Microviable focus and providing access to the real-world clinical needs to address unmet challenges in human health.
About Microviable
Microviable Therapeutics SL, spun out from the Spanish National Research Council in 2016, focused on developing novel technologies and therapeutic products from the microbiota. Over the last years, Microviable lunched a disruptive product for microbiota sampling that has grown exponentially into an international market with clients across fifteen different countries. Moreover, it has developed a unique technology to store human microbiota for downstream therapeutic applications. Currently, Microviable’s platform together with its large and diverse proprietary bacterial culture collection, has enabled the development of two different products, a unique in its kind product of complete microbiota and rationally defined bacterial consortia.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005270/en/
Contact information
Claudio Hidalgo Cantabrana, PhD
claudio.hidalgo@microviable.com
(+34)670034435
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Onego Bio Strengthens Board with Appointment of Dr. Antti Vasara4.2.2026 17:00:00 EET | Press release
Onego Bio, the food ingredient company producing non-animal egg protein through precision fermentation, today announced that Dr. Antti Vasara has joined its board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204881159/en/ Dr. Antti Vasara Dr. Vasara brings more than 25 years of global experience in science, technology, and commercial strategy. Most recently, he served as President and CEO of VTT Technical Research Centre of Finland, where he led one of Europe’s foremost deep tech research organizations. His distinguished career spans senior leadership roles in industry and innovation policy—including impactful work with Nokia and strategic contributions to European research and development initiatives. “Antti is one of the most respected leaders in science and innovation,” said Maija Itkonen, CEO of Onego Bio. “His deep understanding of technology commercialization and ecosystem level strategy will be inva
Andersen Consulting Expands Capabilities with Addition of SHMA4.2.2026 16:30:00 EET | Press release
Andersen Consulting enters into a Collaboration Agreement with SHMA, a leading actuarial and financial advisory firm headquartered in the UAE. SHMA is an actuarial consulting firm with nearly four decades of experience helping organizations navigate complexity, manage risk, and unlock opportunities through actuarial and insurance advisory, risk management, and valuation of End-of-Service Benefits (EOSB). Working with insurance companies, pension schemes, and other private and public organizations, SHMA helps clients build resilient organizations. “At SHMA, we keep quality, customized solutions, and genuine connection with people at the center of our mission,” said Shariq Sikander, director of SHMA. “Collaborating with Andersen Consulting provides us with the opportunity to extend our impact globally and expand our actuarial services beyond the MENA region, bringing innovative, client-focused solutions to organizations seeking practical and transformative approaches to their business ch
Energy Vault announces the Award of 100 MW / 870 MWh Long-Term Energy Service Agreement to its Development Partner in Australia4.2.2026 16:09:00 EET | Press release
Energy Vault Holdings, Inc. (NYSE: NRGV) (“Energy Vault”), a leader in sustainable, grid-scale energy storage solutions, and Bridge Energy Pty Ltd (“Bridge Energy”), an Australian developer bridging the gap between fossil fuels and renewable energy, today announced the Ebor Battery Energy Storage System (BESS) has been awarded a Long-Term Energy Service Agreement (LTESA) by AusEnergy Services. Located in Ebor, within the New England Region of New South Wales (NSW), the 100 MW / 870 MWh project will provide 8 hours of dispatchable capacity. The facility will play a critical role in advancing NSW’s renewable energy targets by providing essential grid firming capacity as aging coal generators retire. The system will charge during periods of excess renewable generation and discharge during peak demand, directly supporting the state’s transition to a decarbonized grid. Subject to obtaining the necessary contractual and regulatory approvals, Energy Vault plans to exercise its option to acqui
Boomi’s Market Momentum Accelerates as Enterprises Standardize on Its AI Activation Platform4.2.2026 16:00:00 EET | Press release
Boomi™, the leader in AI-driven automation, today announced that the company’s momentum in enterprise integration and agentic AI has reached a defining moment, driven by unmatched scale, independent analyst validation, proven customer outcomes, and ecosystem growth. With more than 30,000 customers worldwide — including over a quarter of the Fortune 500 — Boomi’s continued growth reflects the trust the world’s largest enterprises place in its platform.Today, customers rely on Boomi’s unique runtime architecture for mission-critical operations — including over 75,000 AI agents in production — executing billions of dollars in transactions with enterprise-grade reliability and resilience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204745523/en/ Boomi’s Market Momentum Accelerates as Enterprises Standardize on Its AI Activation Platform “Boomi is experiencing the strongest momentum in its history,” said Steve Lucas, Chairm
Ground Investigation for Civil Infrastructure Gets More Robust With Integration of Lab and Field Geotechnical Data4.2.2026 16:00:00 EET | Press release
Seequent, The Bentley Subsurface Company, has streamlined laboratory testing in OpenGround, the leading cloud-connected geotechnical data management solution. The new OpenGround Labs capability enables seamless transfer of soil and rock sample data from field collection to laboratory testing and reporting, with results delivered directly to engineers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204539856/en/ Geotechnical labs can generate Atterberg limits test certificates from raw lab test data in OpenGround. The advancement enables an end-to-end digital engineering-to-lab workflow, enhancing collaboration and improving efficiency between ground investigation and laboratory testing teams. “Trusted Lab testing data is vital for developing our understanding of ground conditions and for the creation of robust geotechnical reports on major infrastructure projects,” said Carl Grice, Seequent’s Director of Geotechnical Info
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom